Pharmacology, Toxicology and Pharmaceutical Science
Confocal Microscopy
100%
Bone Disease
100%
Aggrecan
100%
Chronic Kidney Failure
100%
Vitamin D
100%
Kidney Failure
100%
Fluorochrome
100%
Hypovitaminosis D
100%
Vitamin D Deficiency
100%
Growth Retardation
100%
Vitamin D Receptor
100%
Messenger RNA
100%
Medicine and Dentistry
Maturation
100%
Kidney Function
100%
Epiphyseal Plate
100%
Chondrocyte
50%
Pediatrics Patient
50%
In Vitro
25%
Programmed Cell Death
25%
Cell Line
25%
Ossification
25%
Confocal Microscopy
25%
Growth Retardation
25%
Bone Disease
25%
Cancellous Bone
25%
Aggrecan
25%
Chronic Kidney Disease
25%
X-Ray Microtomography
25%
Renal Failure
25%
Bone Development
25%
Fluorochrome
25%
Vitamin D Deficiency
25%
Vitamin D
25%
Hypovitaminosis D
25%
Vitamin D Receptor
25%
Messenger RNA
25%
In Situ Hybridization
25%
Biochemistry, Genetics and Molecular Biology
Maturation
100%
Kidney Function
100%
Chondrocyte
100%
Vitamin D
100%
Ossification
50%
Micro-Computed Tomography
50%
Confocal Microscopy
50%
Aggrecan
50%
Bone Development
50%
Hypovitaminosis D
50%
Messenger RNA
50%
In Situ Hybridization
50%
Porosity
50%
Keyphrases
Young Rats
100%
1,25(OH)2D3
100%
Normal Renal Function
100%
Bone Architecture
100%
Growth Plate Maturation
100%
Pediatric Patients
16%
Growth Plate
16%
Growth Retardation
8%
Negative Effects
8%
Narrow Distribution
8%
Femur
8%
Inhibiting Effect
8%
Experimental Protocol
8%
Bone Formation
8%
Trabecular number
8%
Detrimental Effects
8%
Confocal Microscopy
8%
Hypertrophic Zone
8%
In Situ Hybridization
8%
Trabecular Bone
8%
Chondrocyte Apoptosis
8%
Aggrecan
8%
Chronic Kidney Disease
8%
Chondrocyte Maturation
8%
Bone Development
8%
Histological Analysis
8%
Vitamin D
8%
In Vivo Applications
8%
Renal Insufficiency
8%
Collagen X
8%
Fluorochrome
8%
Trabecular Thickness
8%
Vitamin D Deficiency
8%
Intracortical
8%
CT Analysis
8%
ATDC5
8%
Cortical Thickness
8%
Tibial Growth Plate
8%
Mineral Disorders
8%
Chondrocyte Proliferation
8%
Vitamin D Receptor Activation
8%
Bone Disorders
8%
Cortical Porosity
8%
Collagen II
8%